Nautilus Biotechnology Profit Margin

Nautilus Biotechnology (NAUT) currently reports a profit margin of -29747.89% as of June 2026. That is below the Healthcare sector average of 15.29%. Use the charts on this page to explore Nautilus Biotechnology's profit margin history and peer comparisons.

Nautilus Biotechnology's profit margin of -29747.89% is lower than the Healthcare sector average of 15.29%. That is roughly 194621.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Nautilus Biotechnology's current -29747.89% should be judged against Healthcare norms (sector average: 15.29%) and against NAUT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -29747.89%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.29%. From there, open related valuation or income-statement pages for Nautilus Biotechnology, and consider following NAUT for alerts when major investors trade the stock.

Nautilus Biotechnology is classified in the Healthcare sector. On profit margin, it currently shows -29747.89% versus a sector average near 15.29%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NAUT with unrelated industries.